Mucosal HIV vaccines: A holy grail or a dud?

Mohan, 2007, Gastrointestinal disease in simian immunodeficiency virus-infected rhesus macaques is characterized by proinflammatory dysregulation of the interleukin-6-Janus kinase/signal transducer and activator of transcription3 pathway, Am J Pathol, 171, 1952, 10.2353/ajpath.2007.070017 Markel, 2005, The search for effective HIV vaccines, N Engl J Med, 353, 753, 10.1056/NEJMp058146 Stevceva, 2004, Mucosal HIV vaccines: where are we now?, Curr HIV Res, 2, 1, 10.2174/1570162043485004 Iijima, 2009, Mucosal immune defense against sexually transmitted diseases, Nippon Rinsho, 67, 2 Iwasaki, 2007, Mucosal dendritic cells, Annu Rev Immunol, 25, 381, 10.1146/annurev.immunol.25.022106.141634 Demberg, 2009, Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design, Int Rev Immunol, 28, 20, 10.1080/08830180802684331 Jepson, 1998, M cells and their role in infection, Trends Microbiol, 6, 359, 10.1016/S0966-842X(98)01337-7 Lee, 1985, Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80, J Exp Med, 161, 475, 10.1084/jem.161.3.475 Smith, 2003, Macrophage HIV-1 infection and the gastrointestinal tract reservoir, J Leukoc Biol, 74, 642, 10.1189/jlb.0503219 Smith, 1997, Infection of gastrointestinal tract macrophages by HIV-1, J Leukoc Biol, 62, 72, 10.1002/jlb.62.1.72 Brenchley, 2004, CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract, J Exp Med, 200, 749, 10.1084/jem.20040874 Guadalupe, 2003, Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy, J Virol, 77, 11708, 10.1128/JVI.77.21.11708-11717.2003 Li, 2005, Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells, Nature, 434, 1148, 10.1038/nature03513 Mattapallil, 2005, Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection, Nature, 434, 1093, 10.1038/nature03501 Mehandru, 2004, Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract, J Exp Med, 200, 761, 10.1084/jem.20041196 Dumais, 2002, Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge, J Infect Dis, 186, 1098, 10.1086/344232 Kaul, 1999, HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers, AIDS, 13, 23, 10.1097/00002030-199901140-00004 Matoba, 2004, A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs, Proc Natl Acad Sci USA, 101, 13584, 10.1073/pnas.0405297101 Hoffmann, 1999, Phylogenetic perspectives in innate immunity, Science, 284, 1313, 10.1126/science.284.5418.1313 Fortis, 2005, Dendritic cells and natural killer cells in the pathogenesis of HIV infection, Immunol Res, 33, 1, 10.1385/IR:33:1:001 Poles, 2003, Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy, J Virol, 77, 10456, 10.1128/JVI.77.19.10456-10467.2003 Chen, 2003, Adaptive immune response of Vgamma2Vdelta2 T cells: a new paradigm, Trends Immunol, 24, 213, 10.1016/S1471-4906(03)00032-2 Targan, 1995, Definition of a lamina propria T cell responsive state enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway, J Immunol, 154, 664, 10.4049/jimmunol.154.2.664 Parker, 1990, Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire, J Exp Med, 171, 1597, 10.1084/jem.171.5.1597 Poccia, 2002, Innate T-cell immunity in HIV infection: the role of Vgamma9Vdelta2 T lymphocytes, Curr Mol Med, 2, 769, 10.2174/1566524023361880 Gougeon, 2002, Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?, Vaccine, 20, 1938, 10.1016/S0264-410X(02)00070-1 Li, 2008, Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China, Clin Infect Dis, 46, 1466, 10.1086/587107 Tsang, 2009, HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation, AIDS, 23, 2255, 10.1097/QAD.0b013e328331a4ce Noursadeghi, 2009, Genome-wide innate immune responses in HIV-1-infected macrophages are preserved despite attenuation of the NF-kappa B activation pathway, J Immunol, 182, 319, 10.4049/jimmunol.182.1.319 Smith, 2000, Biological parameters of HIV-1 infection in primary intestinal lymphocytes and macrophages, J Leukoc Biol, 68, 360, 10.1189/jlb.68.3.360 Lehner, 1995, Genital-associated lymphoid tissue in female non-human primates, Adv Exp Med Biol, 371A, 357, 10.1007/978-1-4615-1941-6_75 Lehner, 2003, Innate and adaptive mucosal immunity in protection against HIV infection, Vaccine, 21, S68, 10.1016/S0264-410X(03)00204-4 Lehner, 1994, Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen, J Virol, 68, 1624, 10.1128/JVI.68.3.1624-1632.1994 Lehner, 1991, Mucosal transmission of HIV, Nature, 353, 709, 10.1038/353709c0 Cocchi, 1995, Identification of RANTES MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells, Science, 270, 1811, 10.1126/science.270.5243.1811 Ross, 1999, Role of chemokine receptors in HIV-1 infection and pathogenesis, Adv Virus Res, 52, 233, 10.1016/S0065-3527(08)60300-0 Chung, 2009, Rapid degranulation of NK cells following activation by HIV-specific antibodies, J Immunol, 182, 1202, 10.4049/jimmunol.182.2.1202 Banchereau, 1998, Dendritic cells and the control of immunity, Nature, 392, 245, 10.1038/32588 Neutra, 2006, Mucosal vaccines: the promise and the challenge, Nat Rev Immunol, 6, 148, 10.1038/nri1777 Lodoen, 2006, Natural killer cells as an initial defense against pathogens, Curr Opin Immunol, 18, 391, 10.1016/j.coi.2006.05.002 Kaser, 2004, Natural killer T cells in mucosal homeostasis, Ann N Y Acad Sci, 1029, 154, 10.1196/annals.1309.032 Mselle, 2007, Unique characteristics of NK cells throughout the human female reproductive tract, Clin Immunol, 124, 69, 10.1016/j.clim.2007.04.008 Yu, 2010, CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK cell subsets, Blood, 115, 274, 10.1182/blood-2009-04-215491 Jacobs, 2005, Mutual interference of HIV and natural killer cell-mediated immune response, Mol Immunol, 42, 239, 10.1016/j.molimm.2004.06.021 Jennes, 2006, Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands, J Immunol, 177, 6588, 10.4049/jimmunol.177.10.6588 Borg, 2004, NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs, Blood, 104, 3267, 10.1182/blood-2004-01-0380 Guan, 2007, NK cells enhance dendritic cell response against parasite antigens via NKG2D pathway, J Immunol, 179, 590, 10.4049/jimmunol.179.1.590 Cella, 2009, A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity, Nature, 457, 722, 10.1038/nature07537 Mowat, 2005, Oral tolerance physiologic basis and clinical applications, 487 Mestecky, 2007, Perspectives on mucosal vaccines: is mucosal tolerance a barrier?, J Immunol, 179, 5633, 10.4049/jimmunol.179.9.5633 Zinkernagel, 1997, Antiviral immunity, Immunol Today, 18, 258, 10.1016/S0167-5699(97)80017-5 Jackson, 2000, False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens, AIDS Res Hum Retroviruses, 16, 595, 10.1089/088922200309016 Kozlowski, 1999, Mucosal vaccination strategies for women, J Infect Dis, 179, S493, 10.1086/314810 Holmgren, 2003, Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges, Vaccine, 21, S89, 10.1016/S0264-410X(03)00206-8 Sheldrake, 1984, Selective transport of serum-derived IgA into mucosal secretions, J Immunol, 132, 363, 10.4049/jimmunol.132.1.363 Rodriguez, 2005, Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG, Vaccine, 23, 2565 Davids, 2006, Polymeric immunoglobulin receptor in intestinal immune defense against the lumen-dwelling protozoan parasite Giardia, J Immunol, 177, 6281, 10.4049/jimmunol.177.9.6281 Hirbod, 2008, HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers, AIDS, 22, 727, 10.1097/QAD.0b013e3282f56b64 Iqbal, 2008, Mucosal innate immunity as a determinant of HIV susceptibility, Am J Reprod Immunol, 59, 44 Kaul, 2001, Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection, AIDS, 15, 431, 10.1097/00002030-200102160-00026 Dorrell, 2000, Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia, AIDS, 14, 1117, 10.1097/00002030-200006160-00008 Fiore, 2000, Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding, New Microbiol, 23, 85 Belec, 1989, Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women, J Infect Dis, 160, 385, 10.1093/infdis/160.3.385 Buchacz, 2001, HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men, AIDS Res Hum Retroviruses, 17, 1689, 10.1089/08892220152741388 Burns, 1996, Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity, Science, 272, 104, 10.1126/science.272.5258.104 Lamm, 1995, IgA and mucosal defense, APMIS, 103, 241, 10.1111/j.1699-0463.1995.tb01101.x Mazanec, 1993, A three-tiered view of the role of IgA in mucosal defense, Immunol Today, 14, 430, 10.1016/0167-5699(93)90245-G Scamurra, 2002, Mucosal plasma cell repertoire during HIV-1 infection, J Immunol, 169, 4008, 10.4049/jimmunol.169.7.4008 Miller, 2003, Anti-HIV and -SIV immunity in the vagina, Int Rev Immunol, 22, 65, 10.1080/08830180305230 Mestecky, 2007, Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites, J Reprod Immunol, 73, 86, 10.1016/j.jri.2007.01.006 Israel, 1995, Nonclassical mucosal antibodies predominate in genital secretions of HIV-1 infected chimpanzees, J Med Primatol, 24, 53, 10.1111/j.1600-0684.1995.tb00146.x Schafer, 2002, Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques, Gut, 50, 608, 10.1136/gut.50.5.608 Baba, 2000, Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection, Nat Med, 6, 200, 10.1038/72309 Mascola, 2000, Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies, Nat Med, 6, 207, 10.1038/72318 Veazey, 2003, Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120, Nat Med, 9, 343, 10.1038/nm833 Martins, 2010, T-cell correlates of vaccine efficacy after a heterologous SIV challenge, J Virol, 84, 4352, 10.1128/JVI.02365-09 Reynolds, 2008, Macaques vaccinated with live-attenuated SIV control replication of heterologous virus, J Exp Med, 205, 2537, 10.1084/jem.20081524 White, 2007, Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV), Blood, 109, 3873, 10.1182/blood-2006-09-045278 Gulzar, 2004, CD8+ T-cells: function and response to HIV infection, Curr HIV Res, 2, 23, 10.2174/1570162043485077 Maecker, 2003, T cell immunity to HIV: defining parameters of protection, Curr HIV Res, 1, 249, 10.2174/1570162033485294 Daar, 1984, The detailed distribution of HLA-A, B, C antigens in normal human organs, Transplantation, 38, 287, 10.1097/00007890-198409000-00018 Li, 2009, Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection, Science, 323, 1726, 10.1126/science.1168676 Kivisakk, 2006, Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy, BMC Immunol, 7, 14, 10.1186/1471-2172-7-14 Cromwell, 2000, Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus, J Virol, 74, 8762, 10.1128/JVI.74.18.8762-8766.2000 Sun, 2009, Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys, J Virol, 83, 10596, 10.1128/JVI.01170-09 Kaufman, 2008, Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination, J Immunol, 181, 4188, 10.4049/jimmunol.181.6.4188 Campbell, 2002, Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues, J Exp Med, 195, 135, 10.1084/jem.20011502 Kaufman, 2009, Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity, Clin Exp Immunol, 157, 165, 10.1111/j.1365-2249.2009.03927.x Kantele, 1999, Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans, J Immunol, 162, 5173, 10.4049/jimmunol.162.9.5173 Barnett, 2008, Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope, AIDS, 22, 339, 10.1097/QAD.0b013e3282f3ca57 Mercier, 2007, Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules, Vaccine, 25, 8687, 10.1016/j.vaccine.2007.10.030 Ishikawa, 2007, Curriculum vitae of intestinal intraepithelial T cells: their developmental and behavioral characteristics, Immunol Rev, 215, 154, 10.1111/j.1600-065X.2006.00473.x Kanamori, 1996, Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lympho-hemopoietic progenitors develop, J Exp Med, 184, 1449, 10.1084/jem.184.4.1449 Johansson-Lindbom, 2007, Generation of gut-homing T cells and their localization to the small intestinal mucosa, Immunol Rev, 215, 226, 10.1111/j.1600-065X.2006.00482.x Mowat, 2003, Anatomical basis of tolerance and immunity to intestinal antigens, Nat Rev Immunol, 3, 331, 10.1038/nri1057 Kiyono, 2004, Nat Rev Immunol, 4, 699, 10.1038/nri1439 Mestecky, 2005, Immunologic uniqueness of the genital tract: challenge for vaccine development, Am J Reprod Immunol, 53, 208, 10.1111/j.1600-0897.2005.00267.x Cole, 2006, Innate host defense of human vaginal and cervical mucosae, Curr Top Microbiol Immunol, 306, 199, 10.1007/3-540-29916-5_8 Parr, 1990, A comparison of antibody titres in mouse uterine fluid after immunization by several routes, and the effect of the uterus on antibody titres in vaginal fluid, J Reprod Fertil, 89, 619, 10.1530/jrf.0.0890619 Haneberg, 1994, Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces, Infect Immun, 62, 15, 10.1128/IAI.62.1.15-23.1994 Kozlowski, 1997, Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women, Infect Immun, 65, 1387, 10.1128/IAI.65.4.1387-1394.1997 Kato, 2000, Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses, Vaccine, 18, 1151, 10.1016/S0264-410X(99)00385-0 Curran, 2009, Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses, Vaccine, 27, 6791, 10.1016/j.vaccine.2009.08.088 Wu, 2000, Generation of female genital tract antibody responses by local or central (common) mucosal immunization, Infect Immun, 68, 5539, 10.1128/IAI.68.10.5539-5545.2000 Crowley-Nowick, 1995, Normal uterine cervix: characterization of isolated lymphocyte phenotypes and immunoglobulin secretion, Am J Reprod Immunol, 34, 241, 10.1111/j.1600-0897.1995.tb00948.x Pudney, 1995, Immunobiology of the human penile urethra, Am J Pathol, 147, 155 Lu, 1999, Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle, Infect Immun, 67, 6321, 10.1128/IAI.67.12.6321-6328.1999 Gallichan, 2001, Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract, J Immunol, 166, 3451, 10.4049/jimmunol.166.5.3451 Shacklett, 2009, Cell-mediated immunity to HIV in the female reproductive tract, J Reprod Immunol, 83, 190, 10.1016/j.jri.2009.07.012 Pialoux, 2008, Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study, Vaccine, 26, 2657, 10.1016/j.vaccine.2007.11.002 Holmgren, 2005, Mucosal immunity and vaccines, Nat Med, 11, S45, 10.1038/nm1213 Lagranderie, 1998, A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes, AIDS Res Hum Retroviruses, 14, 1625, 10.1089/aid.1998.14.1625 Hamajima, 2002, Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine, Clin Immunol, 102, 12, 10.1006/clim.2001.5141 Wang, 2004, An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS, AIDS Res Hum Retroviruses, 20, 846, 10.1089/0889222041725253 Lindenburg, 2002, Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression, Vaccine, 20, 2343, 10.1016/S0264-410X(02)00102-0 Russell, 1996, Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit, Infect Immun, 64, 1272, 10.1128/IAI.64.4.1272-1283.1996 Imaoka, 1998, Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues, J Immunol, 161, 5952, 10.4049/jimmunol.161.11.5952 Moldoveanu, 1995, Human immune responses to influenza virus vaccines administered by systemic or mucosal routes, Vaccine, 13, 1006, 10.1016/0264-410X(95)00016-T Bergquist, 1997, Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina, Infect Immun, 65, 2676, 10.1128/IAI.65.7.2676-2684.1997 Durrani, 1998, Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization, J Immunol Methods, 220, 93, 10.1016/S0022-1759(98)00145-8 Partidos, 1996, Structural requirements for synthetic immunogens to induce measles virus specific CTL responses, Mol Immunol, 33, 1223, 10.1016/S0161-5890(96)00094-6 Vajdy, 2006, Intranasal delivery of vaccines against HIV, Expert Opin Drug Deliv, 3, 247, 10.1517/17425247.3.2.247 Pun, 2009, Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses, Int Immunopharmacol, 9, 468, 10.1016/j.intimp.2009.01.012 Brave, 2008, Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses, Vaccine, 26, 5075, 10.1016/j.vaccine.2008.03.066 Akagi, 2003, Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice, J Med Virol, 69, 163, 10.1002/jmv.10279 Miyake, 2004, Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques, J Med Virol, 73, 368, 10.1002/jmv.20100 Wang, 2007, Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120, J Virol, 81, 10009, 10.1128/JVI.00489-07 Mantis, 2001, Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies, Vaccine, 19, 3990, 10.1016/S0264-410X(01)00115-3 Eo, 2001, Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules, J Immunol, 166, 5473, 10.4049/jimmunol.166.9.5473 Bruhl, 1998, An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice, AIDS Res Hum Retroviruses, 14, 401, 10.1089/aid.1998.14.401 Manrique, 2008, DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory, AIDS Res Hum Retroviruses, 24, 505, 10.1089/aid.2007.0191 Zhou, 2007, Comparative evaluation of oral and intranasal priming with replication-competent adenovirus five host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251), Vaccine, 25, 8021, 10.1016/j.vaccine.2007.09.017 Bradney, 2002, Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization, J Virol, 76, 517, 10.1128/JVI.76.2.517-524.2002 Lewis, 2009, Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin, PLoS One, 4, e6999, 10.1371/journal.pone.0006999 Mutsch, 2004, Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland, N Engl J Med, 350, 896, 10.1056/NEJMoa030595 Fooks, 2000, Development of oral vaccines for human use, Curr Opin Mol Ther, 2, 80 Grdic, 1999, The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action, Eur J Immunol, 29, 1774, 10.1002/(SICI)1521-4141(199906)29:06<1774::AID-IMMU1774>3.0.CO;2-1 Czerkinsky, 2009, Enteric vaccines for the developing world: a challenge for mucosal immunology, Mucosal Immunol, 2, 284, 10.1038/mi.2009.22 Goubier, 2008, Plasmacytoid dendritic cells mediate oral tolerance, Immunity, 29, 464, 10.1016/j.immuni.2008.06.017 Fujihashi, 2004, Mucosal immunity and tolerance in the elderly, Mech Ageing Dev, 125, 889, 10.1016/j.mad.2004.05.009 Shiokawa, 2009, IL-10 and IL-27 producing dendritic cells capable of enhancing IL-10 production of T cells are induced in oral tolerance, Immunol Lett, 125, 7, 10.1016/j.imlet.2009.05.002 Fujihashi, 2001, Peyer's patches are required for oral tolerance to proteins, Proc Natl Acad Sci USA, 98, 3310, 10.1073/pnas.061412598 Kihira, 1995, Induction of IgA B cell differentiation of bone marrow-derived B cells by Peyer's patch autoreactive helper T cells, Immunol Invest, 24, 701, 10.3109/08820139509060699 Goodrich, 1999, Effect of intestinal epithelial cell cytokines on mucosal B-cell IgA secretion: enhancing effect of epithelial-derived IL-6 but not TGF-beta on IgA+ B cells, Immunol Lett, 67, 11, 10.1016/S0165-2478(98)00112-6 Misumi, 2009, Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer, J Immunol, 182, 6061, 10.4049/jimmunol.0802928 Cubillos, 2008, Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide, J Virol, 82, 7223, 10.1128/JVI.00401-08 Rajkannan, 2006, Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles, Vaccine, 24, 5149, 10.1016/j.vaccine.2006.04.011 Wells, 2008, Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria, Nat Rev Microbiol, 6, 349, 10.1038/nrmicro1840 Wang, 2009, Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity, J Virol, 83, 7166, 10.1128/JVI.00374-09 Wright, 2004, Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein, J Infect Dis, 189, 1221, 10.1086/382088 Takamura, 2004, DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration, Gene Ther, 11, 628, 10.1038/sj.gt.3302193 DeVico, 2002, Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1, Vaccine, 20, 1968, 10.1016/S0264-410X(02)00080-4 Kaneko, 2000, Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein, Virology, 267, 8, 10.1006/viro.1999.0093 Forsman, 2003, Uptake of amplifiable fragments of retrotransposon DNA from the human alimentary tract, Mol Genet Genomics, 270, 362, 10.1007/s00438-003-0930-3 Lambert, 2001, A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects, Vaccine, 19, 3033, 10.1016/S0264-410X(01)00051-2 Kotton, 2006, Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system, Vaccine, 24, 6216, 10.1016/j.vaccine.2006.05.094 Mann, 2006, Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity, Methods, 38, 90, 10.1016/j.ymeth.2005.11.002 Mann, 2009, Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection, Vaccine, 27, 3643, 10.1016/j.vaccine.2009.03.040 Azizi, 2008, Induction of broad cross-subtype-specific HIV-1 immune responses by a novel multivalent HIV-1 peptide vaccine in cynomolgus macaques, J Immunol, 180, 2174, 10.4049/jimmunol.180.4.2174 Wilson-Welder, 2008, Vaccine adjuvants: current challenges and future approaches, J Pharm Sci, 98, 1278 Decroix, 2002, Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41, Scand J Immunol, 56, 59, 10.1046/j.1365-3083.2002.01113.x Singh, 2003, Recent advances in veterinary vaccine adjuvants, Int J Parasitol, 33, 469, 10.1016/S0020-7519(03)00053-5 Cholera vaccines, WHO position paper. Wkly Epidemiol Rec 2001;76(Apr):117–24. Holmgren, 1993, Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems, Vaccine, 11, 1179, 10.1016/0264-410X(93)90039-Z Boberg, 2008, Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin, Vaccine, 26, 5079, 10.1016/j.vaccine.2008.03.096 Couch, 2009, Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans, Vaccine, 27, 5344, 10.1016/j.vaccine.2009.06.084 Chionh, 2009, M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens, Infect Immun, 77, 2962, 10.1128/IAI.01522-08 Scavone, 2009, Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract, Microbiol Immunol, 53, 233, 10.1111/j.1348-0421.2009.00111.x Holmgren, 2005, Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA, Immunol Lett, 97, 181, 10.1016/j.imlet.2004.11.009 Sanchez, 2005, Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea, Curr Opin Immunol, 17, 388, 10.1016/j.coi.2005.06.007 George-Chandy, 2001, Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells, Infect Immun, 69, 5716, 10.1128/IAI.69.9.5716-5725.2001 Lavelle, 2003, Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation, J Immunol, 171, 2384, 10.4049/jimmunol.171.5.2384 Porzio, 2004, Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria, BMC Biotechnol, 4, 27, 10.1186/1472-6750-4-27 Eriksson, 2003, Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development, Infect Immun, 71, 1740, 10.1128/IAI.71.4.1740-1747.2003 Cox, 1991, Experimental induction of diarrhoea in newly-weaned piglets, Zentralbl Veterinarmed A, 38, 418, 10.1111/j.1439-0442.1991.tb01030.x Lycke, 2001, The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses, Curr Opin Mol Ther, 3, 37 Eriksson, 2003, The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability, Vaccine, 22, 185, 10.1016/S0264-410X(03)00567-X Sundling, 2008, CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization, J Gen Virol, 89, 2954, 10.1099/vir.0.2008/005470-0 Kindrachuk, 2008, Activation and regulation of toll-like receptor 9: CpGs and beyond, Mini Rev Med Chem, 8, 590, 10.2174/138955708784534481 Bird, 1986, CpG-rich islands and the function of DNA methylation, Nature, 321, 209, 10.1038/321209a0 Daftarian, 2003, Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge, J Immunol, 171, 4028, 10.4049/jimmunol.171.8.4028 Jiang, 2005, CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides, J Virol, 97, 393, 10.1128/JVI.79.1.393-400.2005 Horner, 2001, Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites, J Immunol, 167, 1584, 10.4049/jimmunol.167.3.1584 Rharbaoui, 2004, The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues, Infect Immun, 72, 6978, 10.1128/IAI.72.12.6978-6986.2004 Becker, 2006, The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant, Vaccine, 24, 5269, 10.1016/j.vaccine.2005.11.008 Kamijuku, 2008, Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses, Mucosal Immunol, 1, 208, 10.1038/mi.2008.2 Ko, 2005, alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor, J Immunol, 175, 3309, 10.4049/jimmunol.175.5.3309 Courtney, 2009, Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens, Vaccine, 27, 3335, 10.1016/j.vaccine.2009.01.083 Huang, 2008, Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide, Vaccine, 26, 1807, 10.1016/j.vaccine.2008.02.002 Uchida, 2008, Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer, Cancer Immunol Immunother, 57, 337, 10.1007/s00262-007-0373-5 Belyakov, 1998, Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge, Proc Natl Acad Sci USA, 95, 1709, 10.1073/pnas.95.4.1709 Leonard, 1997, Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production, Blood, 90, 2541 Gupta, 2007, M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B, J Drug Target, 15, 701, 10.1080/10611860701637982 Jaganathan, 2006, Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally, Vaccine, 24, 4201, 10.1016/j.vaccine.2006.01.011 Foged, 2005, Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition, Vaccine, 22, 1903 Steers, 2009, Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines, Vaccine, 27, 6939, 10.1016/j.vaccine.2009.08.105 Sakaue, 2003, HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses, J Immunol, 170, 495, 10.4049/jimmunol.170.1.495